By admin 
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to accelerating the development of life-saving treatments for pediatric cancer, has officially announced the appointment of Osama Alsaleh to its Board of Directors. Alsaleh, a distinguished leader in healthcare innovation and venture capital, brings a multifaceted background in strategic partnerships, health equity, and technology to the organization. His appointment comes at a critical juncture for the pediatric oncology sector, which continues to face significant hurdles in securing private investment and navigating the complex pathway from laboratory research to clinical application. As the Head of Partnerships at Plug and Play Health—the healthcare arm of one of the world’s most active venture capital firms and global innovation platforms—Alsaleh is positioned to bridge the gap between early-stage medical breakthroughs and the scalable resources required to bring them to the bedside of young patients.
The addition of Alsaleh to the CureSearch leadership team reflects a broader strategic shift within the non-profit sector toward "venture philanthropy." This model applies the rigor and networking capabilities of venture capital to charitable giving, ensuring that donor dollars are channeled into projects with the highest potential for clinical impact. Alsaleh’s career has been defined by a commitment to advancing global healthcare solutions through cross-industry collaboration, making him a vital asset for CureSearch as it seeks to expand its reach and accelerate the pace of pediatric drug development.
A Career Defined by Innovation and Global Impact
Osama Alsaleh’s professional trajectory illustrates a deep-seated commitment to transforming healthcare delivery through technology and strategic investment. Before joining Plug and Play Health, Alsaleh held several high-impact roles within the healthcare technology ecosystem. At Oracle Health (formerly Cerner), he was instrumental in shaping the company’s approach to health equity. He spearheaded the creation of Oracle’s health equity team, where he developed transformative strategies focused on social determinants of health (SDoH), accessibility, and the ethical implementation of healthcare algorithms.
During his tenure at Oracle, Alsaleh also served on the Oracle Charitable Foundation Clinical Decision Committee. In this capacity, he contributed to the evaluation and allocation of more than $42 million in healthcare grants. This experience provided him with a unique vantage point on the challenges of funding medical research, particularly in identifying projects that demonstrate both scientific excellence and a viable path toward commercialization and patient access.
His expertise is not limited to the private sector; Alsaleh has consistently engaged with global and governmental entities to address systemic healthcare challenges. He has served as a global advocate for sustainable health solutions, collaborating with the World Bank Group and the World Health Organization (WHO). His regulatory acumen was further demonstrated through his advisory roles on quality reporting measures and his work with United States federal agencies. Notably, he collaborated with industry leaders on Centers for Medicare & Medicaid Services (CMS) initiatives and provided insights to the White House COVID-19 Taskforce and the U.S. State Department during the height of the global pandemic. This breadth of experience allows him to navigate the intricate regulatory and policy landscapes that often dictate the success or failure of new pediatric therapies.
Addressing the Pediatric Funding Crisis
The appointment of a venture capital expert like Alsaleh highlights a persistent and sobering reality in the medical field: the "funding gap" for pediatric oncology. While cancer remains the leading cause of death by disease for children in the United States, pediatric research receives only a small fraction of the funding directed toward adult cancers. According to data from the National Cancer Institute (NCI), only about 4% of the federal budget for cancer research is specifically dedicated to pediatric cancers.
This disparity is even more pronounced in the private sector. Traditional venture capital firms often view pediatric oncology as a "small market" compared to adult oncology, which targets diseases like breast, lung, or prostate cancer that affect millions of people. Because pediatric cancers are considered rare diseases, the return on investment (ROI) for pharmaceutical companies and private investors is often perceived as lower, leading to what researchers call the "Valley of Death"—the phase where promising lab discoveries fail to transition into clinical trials due to a lack of funding.
Alsaleh’s background at Plug and Play Health, which bridges the gap between startups and corporate giants, is intended to directly address this challenge. By bringing a venture-oriented mindset to the CureSearch board, he aims to attract new technologies and strategic partners to the pediatric space. His work focuses on identifying innovative startups that can adapt adult cancer treatments for pediatric use or develop entirely new modalities specifically for children.
Chronology of Leadership and Organizational Evolution
The integration of Alsaleh into the CureSearch Board follows a series of strategic moves by the organization to modernize its approach to research funding. CureSearch has moved away from traditional broad-based academic grants toward a more focused "Catapult" model. This model prioritizes research that is nearing the clinical trial stage, providing the necessary funding and regulatory guidance to push treatments through the final stages of development.
- Early 2010s: CureSearch shifts its focus toward "acceleration" grants, identifying the need for faster drug development cycles.
- 2020-2022: During the global pandemic, the organization recognizes the vulnerability of pediatric clinical trials and begins seeking leaders with expertise in digital health and resilient supply chains.
- 2023: CureSearch expands its industry partnerships, recognizing that collaboration with the tech and VC sectors is essential for long-term sustainability.
- 2024: Osama Alsaleh is appointed to the Board of Directors, signaling a commitment to leveraging global innovation ecosystems to solve pediatric oncology challenges.
Official Responses and Strategic Vision
The leadership at CureSearch has expressed high expectations for the impact of Alsaleh’s appointment. Jared Brancazio, Chair of the CureSearch Board of Directors, emphasized the importance of Alsaleh’s unique professional network and his ability to synthesize different sectors of the healthcare economy.
"Osama brings a unique and highly valuable perspective to CureSearch," Brancazio stated. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer. We are excited to have him join the board at this important time for our organization."
For his part, Alsaleh has been vocal about the systemic inequities in how medical innovation is funded. He views his role on the board as a way to correct the underrepresentation of pediatric needs in the broader venture capital world.
"Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underfunded and underrepresented within mainstream venture capital and innovation ecosystems," Alsaleh remarked. "By leveraging my network across venture capital, startups, healthcare institutions, and technology companies, I aim to help attract new technologies, strategic partners, and resources that can accelerate progress toward cures for children with cancer."
Broader Impact and Implications for Pediatric Medicine
The inclusion of a leader from the venture capital and global health sectors on a non-profit board suggests a maturing of the pediatric oncology field. It reflects a realization that philanthropy alone cannot solve the complex problems of drug development. Instead, a multi-stakeholder approach involving non-profits, government agencies, private investors, and technology firms is required.
Alsaleh’s expertise in health equity is particularly relevant as the medical community grapples with disparities in clinical trial access. Historically, children from marginalized communities have had lower rates of enrollment in clinical trials, which can lead to disparities in outcomes. With Alsaleh’s background in shaping Oracle’s health equity strategies, CureSearch is better positioned to ensure that the "new and better treatments" it funds are accessible to all children, regardless of their socioeconomic background or geographic location.
Furthermore, the rise of "precision medicine"—treatments tailored to the genetic profile of an individual’s tumor—requires the kind of high-tech infrastructure and data analytics that Alsaleh has spent his career developing. His experience with Oracle and Cerner, two giants in the electronic health record (EHR) and data management space, will be invaluable as CureSearch navigates the data-heavy landscape of modern genomics and personalized pediatric care.
As CureSearch continues to fund high-impact research through its Acceleration Initiative and Catapult Awards, Alsaleh’s presence on the board is expected to foster a more robust pipeline of candidates for these programs. By identifying promising biotech startups through the Plug and Play ecosystem, he can help funnel cutting-edge science into the CureSearch vetting process, ensuring that the organization remains at the forefront of the fight against childhood cancer.
In conclusion, the appointment of Osama Alsaleh represents more than just a change in leadership; it is a strategic alignment of venture capital expertise with humanitarian goals. For the thousands of children diagnosed with cancer each year, this partnership offers a renewed sense of hope that the next generation of treatments will be developed with the speed, efficiency, and scale that the crisis demands. Through the fusion of innovation, investment, and a relentless focus on the patient, CureSearch and Alsaleh aim to redefine what is possible in the quest to end pediatric cancer.
